Author

Masato Iizuka

Institutions: Tanabe Pharma Corporation (Japan), Fuji Pharma Co., Ltd. (Japan)

Observed institutions: Tanabe Pharma Corporation (Japan), Fuji Pharma Co., Ltd. (Japan)

ORCID: 0009-0001-7711-4124

Observed ORCID: 0009-0001-7711-4124

OpenAlex ID: A5111027213

Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study

2023 · Kazuo Fujihara, Ho Jin Kim, et al. · Multiple Sclerosis and Related Disorders · 11

Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database

2025 · Katsuyoshi Matsuoka, Ataru Igarashi, et al. · Intestinal Research · 5

Impact of estetrol and drospirenone combination therapy on alleviation of the pelvic pain of endometriosis: a randomized control trial

2025 · Tasuku Harada, Masayoshi Nogami, et al. · F&S Reports · 4

Works count: 3

Citation count: 20

H-index: 3

I10-index: 1